Dextroamphetamine generic?

What is the generic name for Dextroamphetamine?

Dextroamphetamine is a brand name for a medication that contains the active ingredient dextroamphetamine saccharate, a central nervous system stimulant used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. The generic name for Dextroamphetamine is dextroamphetamine.

What are some alternatives to Dextroamphetamine?

Other medications that contain dextroamphetamine or dextroamphetamine saccharate include [1] DextroStat, Dexedrine, and ProCentra. However, it's essential to note that these brand names may not be widely available or may be subject to patent protections.

Can generic versions of Dextroamphetamine be purchased?

Yes, generic versions of Dextroamphetamine, containing dextroamphetamine or dextroamphetamine saccharate, are available for purchase. These generic medications are often cheaper than their brand-name counterparts but may not have the same formulations or be manufactured by the same companies.

Pricing and Availability

The cost of generic Dextroamphetamine can vary depending on the manufacturer, dosage, and pharmacy. According to various sources, including [2] DrugPatentWatch.com, the price range for generic Dextroamphetamine can be found between $20-$50 per bottle of 30 pills.

Patent Expiration and Exclusivity

The patent for Dextroamphetamine (dextroamphetamine saccharate) expired in the United States in 2007 [3]. This allows generic manufacturers to produce and market their own versions of the medication without facing patent-related restrictions.

References

[1] Wikipedia. (n.d.). Dextroamphetamine. Retrieved from https://en.wikipedia.org/wiki/Dextroamphetamine

[2] DrugPatentWatch.com. (n.d.). Dextroamphetamine. Retrieved from https://www.drugpatentwatch.com/brand-name/dextroamphetamine

[3] FDA. (n.d.). Exclusivity expiration dates: Dextroamphetamine saccharate, Dextroamphetamine Saccharate, Dextroamphetamine Saccharate, Dextroamphetamine saccharate. Retrieved from https://www.fda.gov/drugs/new-drugs-fda-cders-new-animal-drugs-industry-exclusivity-extensions/exclusivity-expiration-dates